DRAXIMAGE DTPA

DRAXIMAGE DTPA is an FDA-registered drug product whose active ingredient is KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PENTETATE. It is labelled by Jubilant DraxImage Inc., dba Jubilant Radiopharma taken by intravenous and marketed as a human prescription drug product. Identifiers on file: NDC 65174-288, application NDA018511, label effective 20230508. This page reproduces the FDA-approved label text so you can check what a product is, who makes it and how it is supplied before discussing it with a pharmacist or prescriber.

Across FDA labelling, products containing KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PENTETATE are most often described in connection with: pediatric patients, brain imaging, lung ventilation, draximage dtpa, technetium pentetate, renal visualization, estimation glomerular, filtration rate. Wording differs between labels, and the full indications section on this page takes precedence when it is present.

1 INDICATIONS AND USAGE DRAXIMAGE ® DTPA, after radiolabeling with Technetium Tc 99m, is indicated for DRAXIMAGE ® DTPA is a kit for the preparation of Technetium Tc 99m pentetate injection. Technetium Tc 99m pentetate is a radioactive diagnostic agent indicated for: Brain imaging in adults ( 1.1 ). Renal visualization, assessment of renal perfusion, and estimation of glomerular filtration rate in adult and pediatric patients ( 1.2 ). Lung ventilation imaging and evaluation of pulmonary embolism when paired with perfusion imaging in adult and pediatric patients ( 1.3 ). 1.1 Brain Imaging Brain imaging in adults by intravenous administration. 1.2 Renal Scintigraphy Renal visualization, assessment of renal perfusion, and estimation of glomerular filtration rate in adult and pediatric patients by intravenous administration. 1.3 Lung Ventilation Imaging Lung ventilation imaging and evaluation of pulmonary embolism when paired with perfusion imaging in adult and pediatric patients when administered by nebulizer for inhalation.

2 DOSAGE AND ADMINISTRATION During preparation and handling, use water proof gloves and effective shielding, to minimize radiation exposure ( 2.1 , 5.3 ). See the Full Prescribing Information for detailed information regarding recommended Dosage and Image Acquisition Instructions ( 2.2 ) and Instructions for Drug Preparation ( 2.4 ). Do not administer more than one dose ( 2.2 ). 2.1 Radiation Safety – Drug Handling Tc 99m labeled DRAXIMAGE ® DTPA injection is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure to the patient and healthcare worker. During preparation and handling, use water proof gloves and effective shielding, including syringe shields [see Warnings and Precautions ( 5.3 )] . 2.2 Recommended Dosage and Image Acquisition Instructions The recommended dose ranges for intravenous or inhalation administration of DRAXIMAGE® DTPA, after reconstitution, are presented in Table 1 through Table 3. Do not administer more than one dose. Table 1 Tc 99m Labeled DRAXIMAGE ® DTPA Injection – Intravenous Administration, Adults Indication Route of Administration Dose Image Acquisition Brain Imaging Intravenous Injection 370 MBq to 740 MBq (10 mCi to 20 mCi) Immediate dynamic imaging. Obtain at least one blood-pool image in same position as flow. Delayed images can be obtained 1 hour later. Renal Visualization and Perfusion Assessment Intravenous Injection 370 MBq to 740 MBq (10 mCi to 20 mCi) Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. Renal Visualization with Estimation of Glomerular Filtration Rate Intravenous Injection 111 MBq to 185 MBq (3 mCi to 5 mCi) Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. Estimation of Glomerular Filtration Rate (with no renal imaging) Intravenous Injection 7.4 MBq to 18.5 MBq (0.2 mCi to 0.5 mCi) Blood sampling only is performed. Table 2 Tc 99m Labeled DRAXIMAGE ® DTPA Injection – Intravenous Administration, Pediatric Patients Indication Route of Administration Dose Image Acquisition Renal Visualization and Perfusion Assessment Intravenous Injection 3.7 MBq/kg to 7.4 MBq/kg (0.1 mCi/kg to 0.2 mCi/kg) Minimum 37 MBq (1 mCi) Maximum 185 MBq (5 mCi) Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. Estimation of Glomerular Filtration Rate (with no renal imaging) Intravenous Injection 7.4 MBq to 18.5 MBq (0.2 mCi to 0.5 mCi) Blood sampling only is performed. Table 3 Tc 99m Labeled DRAXIMAGE ® DTPA – Aerosol Inhalation Administration * For lung imaging performed after perfusion imaging, target count rate should be approximately three times that of perfusion count rate. Indication Route of Administration Dose Image Acquisition Lung Ventilation Adults Aerosol Inhalation 925 MBq to 1850 MBq (25 mCi to 50 mCi) in the nebulizer to achieve a lung dose of approximately 18.5 MBq to 37 MBq (0.5 mCi to 1.0 mCi) For lung imaging performed prior to perfusion imaging, the target administered dose to the lungs is achieved after 3 to 5 minutes of inhalation or at an imaging count rate of 50,000 to 100,000 per minute * . Lung Ventilation Pediatric Patients Aerosol Inhalation 925 MBq (25 mCi) in the nebulizer to achieve a lung dose of approximately 18.5 MBq (0.5 mCi) For lung imaging performed prior to perfusion imaging, the target administered dose to the lungs is achieved at an imaging count rate of approximately 10,000 to 50,000 per minute * . 2.3 Administration Instructions Use aseptic technique for all drug preparation and handling. Visually inspect the Tc 99m labeled DRAXIMAGE ® DTPA injection after reconstitution for particulate matter prior to administration. Do not use or administer if there is evidence of foreign matter or the solution is not clear. Measure the patient dose by a radioactivity calibration system immediately prior to administration. Intravenous Use Instruct the patient to increase fluid intake and to void frequently for the next 4 to 6 hours after Tc 99m labeled DRAXIMAGE ® DTPA administration by injection to minimize the radiation dose to the bladder. Inhalation Use Use the selected nebulizer in accordance with the manufacturer’s instructions. Instruct the patient to rinse their mouth and expectorate after Tc 99m labeled DRAXIMAGE ® DTPA administration by inhalation to minimize the radiation dose to the mouth and esophagus. 2.4 Instructions for Drug Preparation The prepared solution can either be administered via intravenous injection or aerosolized by nebulizer for inhalation use. Before reconstitution, inspect the integrity of the vial. Add 2 to 10 mL [maximum amount 18.5 gigabecquerels (500 mCi)] of sodium pertechnetate Tc 99m injection USP to the reaction vial. The volume of pertechnetate added should be balanced by the removal of the same volume of air. Cover the vial shield and invert to mix the contents. Assay the preparation in a calibrator, record the radio assay information on the label with radiation warning symbol, and affix it to the reaction vial. After reconstitution, store the solution at 25 °C (77 °F) in a lead shield and discard after 12 hours; excursions permitted between 15 °C and 30 °C (59 °F and 86°F). Allow the preparation to stand for 15 minutes before determining the radiochemical purity of Tc 99m labeled DRAXIMAGE ® DTPA injection. After reconstitution, do not vent the vial. 2.5 Determination of Radiochemical Purity Obtain the following: Two ITLC-SG (1 x 10 cm) 0.9% Sodium Chloride Injection USP (for determination of reduced hydrolyzed technetium) Acetone (for determination of free pertechnetate) Two glass test tubes (18 mm x 150 mm) with stoppers Step 1: System A : Add 1 mL of 0.9% Sodium Chloride Injection USP in an 18 mm x 150 mm test tube. Place the stopper and allow the atmosphere in the tube to equilibrate for 1 minute. System B : Repeat with Acetone in a separate test tube. Step 2: Mark each chromatographic strip with a pencil mark 1.5 cm (see Figure 1 and Figure 2 ) from one end of the strip (mark as origin). Place one drop (approximately 0.01 to 0.02 mL) of the Technetium Tc 99m pentetate injection at the origin. For System A (saline), do not allow the strip to dry. For System B (acetone), dry the strip using a gentle stream of nitrogen gas. Step 3: Place each strip with the origin end towards the bottom of the previously equilibrated test tube to develop (the origin must be above the surface of the solvent). Place stopper in the test tube and keep upright. Step 4: When the solvent front has reached the top of the strip, remove the strip with forceps and allow it to dry. Step 5: System A – Determination of reduced hydrolyzed technetium: In System A (saline), reduced hydrolyzed technetium ( 99m TcO 2 ) stays at the origin (R f 0 to 0.1), while the bound technetium and free pertechnetate ( 99m TcO 4 – ) migrates to the solvent front (R f 0.85 to 1.0). Cut the dried strip 3 cm from the origin. The short piece is marked as Part I and the long piece is marked as Part II . Count the pieces in a counter and determine the percentage of reduced hydrolyzed technetium according to the following formula: Figure 1 System A Diagram System B – Determination of free pertechnetate: In System B (acetone), the bound technetium ( 99m Tc) and reduced hydrolyzed technetium ( 99m TcO 2 ) stay at the origin (R f 0 to 0.1), while free pertechnetate ( 99m TcO 4 – ) migrates to the solvent front (R f 0.85 to 1.0). Cut the dried strip 2 cm from the solvent front end. The short piece is marked Part III and the long piece is marked Part IV . Count the pieces in a counter and determine the percentage of free pertechnetate according to the following formula: Figure 2 System B Diagram Step 6: Determine the radiochemical purity according to the following formula: Use Technetium Tc 99m pentetate injection only if the radiochemical purity is 90% or greater. eq1 Figure_1 eq2 figure2 step-6-formula 2.6 Radiation Dosimetry The estimated radiation absorbed dose to various organs from an intravenous injection of Tc 99m pentetate in patients with normal and abnormal renal function is shown respectively in Table 4 and Table 5 . Table 4 Estimated Radiation Absorbed Dose for Technetium Tc 99m Pentetate Injection in Patients With Normal Renal Function Following Intravenous Injection Absorbed Dose Per Unit Activity Administered (microGy/MBq) Organ Adult 15 Years 10 Years 5 Years 1 Year Adrenals 1.4 1.8 2.7 4.0 7.2 Bone surfaces 2.4 2.9 4.3 6.1 10 Brain 0.86 1.1 1.7 2.8 4.9 Breast 0.72 0.92 1.3 2.2 4.1 Gallbladder wall 1.5 2.1 3.8 5.0 6.1 Gastrointestinal tract Esophagus 1.0 1.3 1.9 3.0 5.4 Stomach wall 1.3 1.7 2.8 4.0 6.8 Small intestine wall 2.5 3.1 4.9 7.0 10 Colon wall 3.1 3.9 6.0 8.1 11 Upper large intestine wall 2.1 2.8 4.3 6.5 9.2 Lower large intestine wall 4.3 5.4 8.2 10 13 Heart wall 1.2 1.5 2.2 3.3 5.9 Kidneys 4.4 5.3 7.5 11 18 Liver 1.2 1.6 2.5 3.8 6.4 Lungs 1.0 1.3 2.0 3.0 5.5 Muscles 1.6 2.0 3.0 4.3 6.8 Ovaries 4.2 5.3 7.7 10 13 Pancreas 1.4 1.8 2.8 4.3 7.4 Red marrow 1.5 1.8 2.7 3.7 5.7 Skin 0.87 1.0 1.7 2.6 4.4 Spleen 1.3 1.6 2.6 3.9 6.8 Testes 2.9 4.0 6.8 9.4 13 Thymus 1.0 1.3 1.9 3.0 5.4 Thyroid 1.0 1.3 2.1 3.3 6.0 Urinary bladder wall 62 78 110 150 170 Uterus 7.9 9.6 15 18 22 Remaining organs 1.7 2.1 3.0 4.2 6.6 Effective dose per unit activity (microSv/MBq) 4.9 6.3 9.4 12 16 Table 5 Estimated Radiation Absorbed Dose for Technetium Tc 99m Pentetate Injection in Patients With Abnormal Renal Function Following Intravenous Injection Absorbed Dose Per Unit Activity Administered (microGy/MBq) Organ Adult 15 Years 10 Years 5 Years 1 Year Adrenals 4.1 5.1 7.6 11 21 Bone surfaces 6.0 7.1 11 15 28 Brain 2.8 3.5 5.7 9.1 16 Breast 2.3 3.0 4.2 6.8 13 Gallbladder wall 4.2 5.7 9.2 13 16 Gastrointestinal tract Esophagus 3.3 4.2 6.2 9.6 17 Stomach wall 3.8 5.0 7.9 11 19 Small intestine wall 4.5 5.6 8.5 13 22 Colon wall 4.5 5.8 8.7 13 22 Upper large intestine wall 4.3 5.6 8.1 13 21 Lower large intestine wall 4.9 6.1 9.5 13 23 Heart wall 3.7 4.7 7.0 10 18 Kidneys 7.7 9.2 13 19 32 Liver 3.7 4.6 7.1 11 19 Lungs 3.3 4.2 6.2 9.5 17 Muscles 3.2 4.0 6.1 9.1 17 Ovaries 5.0 6.2 9.2 14 23 Pancreas 4.3 5.3 8.0 12 21 Red marrow 3.4 4.2 6.4 9.3 16 Skin 2.2 2.6 4.2 6.7 12 Spleen 3.8 4.7 7.3 11 19 Testes 3.5 4.5 6.9 10 18 Thymus 3.3 4.2 6.2 9.6 17 Thyroid 3.4 4.2 6.7 11 19 Urinary bladder wall 21 27 39 50 66 Uterus 6.1 7.4 11 16 25 Remaining organs 3.3 4.1 6.3 9.7 17 Effective dose per unit activity (microSv/MBq) 4.6 5.8 8.7 13 21 The estimated radiation absorbed dose to various organs from the inhalation of Tc 99m Pentetate Injection is shown in Table 6 . Table 6 Estimated Radiation Absorbed Dose for Technetium Tc 99m Pentetate Injection Administered by Inhalation Absorbed Dose Per Unit Activity Administered (microGy/MBq) Organ Adult 15 Years 10 Years 5 Years 1 Year Adrenals 2.1 2.9 4.4 6.7 12 Bone surfaces 1.9 2.4 3.5 5.3 9.8 Breast 1.9 1.9 3.3 4.8 7.8 Gastrointestinal tract Stomach wall 1.7 2.2 3.5 5.1 8.9 Small intestine wall 2.1 2.6 4.1 6.3 11 Upper large intestine wall 1.9 2.4 3.8 6.1 10 Lower large intestine wall 3.2 4.2 6.3 8.8 15 Kidneys 4.1 5.1 7.2 11 19 Liver 1.9 2.5 3.7 5.5 9.7 Lungs 17 26 36 54 100 Ovaries 3.3 4.1 6.1 8.9 15 Pancreas 2.1 2.6 4.0 6.1 11 Red marrow 2.7 3.4 4.7 6.2 9.6 Spleen 1.9 2.4 3.6 5.6 9.9 Testes 2.1 3.1 5.2 7.9 15 Thyroid 0.99 1.7 2.7 4.4 7.8 Urinary bladder wall 47 58 84 120 230 Uterus 5.9 7.2 11 16 27 Other tissue 1.8 2.2 3.2 4.9 8.6 Effective dose per unit activity (microSv/MBq) 5.9 8.0 11 17 31

4 CONTRAINDICATIONS Hypersensitivity to the active ingredient or to any component of the product [see Warnings and Precautions ( 5.1 )]. Hypersensitivity to the active ingredient or any component of this product ( 4 ).

6 ADVERSE REACTIONS The following adverse reactions have been identified post-approval. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their exact frequency or establish a causal relationship to Technetium Tc 99m pentetate exposure. Adverse reactions are presented in decreasing order of reported frequency: Immune system disorders: allergic reaction, anaphylactic reaction, angioedema. Skin and subcutaneous tissue disorders: rash, itching, hives, erythema. Respiratory, thoracic and mediastinal disorders: throat irritation, wheezing. Vascular disorders: hypotension, hypertension. Nervous system disorders: headache, fainting, dizziness. General disorders and administration site conditions: chills. Gastrointestinal disorders: nausea, vomiting. Cardiac disorders: cyanosis, tachycardia. Most common adverse reactions reported with Technetium Tc 99m pentetate injection include allergic reactions, rash, itching ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Jubilant DraxImage Inc. at 1-888-633-5343 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

2 FDA recall record(s) match this product name or manufacturer. A match means the firm or product name appears in the enforcement report; confirm lot numbers and dates against the official FDA notice before acting.

What is DRAXIMAGE DTPA used for?
1 INDICATIONS AND USAGE DRAXIMAGE ® DTPA, after radiolabeling with Technetium Tc 99m, is indicated for DRAXIMAGE ® DTPA is a kit for the preparation of Technetium Tc 99m pentetate injection. Technetium Tc 99m pentetate is a radioactive diagnostic agent indicated for: Brain imaging in adults ( 1.1 ). Renal visualization, assessment of renal perfusion, and estimation of glomerular filtration rate …

Who makes DRAXIMAGE DTPA?
Jubilant DraxImage Inc., dba Jubilant Radiopharma is the labeler of record for DRAXIMAGE DTPA.

What form does DRAXIMAGE DTPA come in?
administered by intravenous. Strengths and pack sizes vary by label, so compare the NDC on your pack with the identifier listed on this page.

Is DRAXIMAGE DTPA prescription or over-the-counter?
The FDA label for this product is recorded as human prescription drug. Marketing status can differ between strengths and countries, so check the dispensing rules where you live.

Has DRAXIMAGE DTPA been recalled?
2 FDA recall record(s) match this product name or manufacturer. Review the recall and safety notices section on this page and confirm lot numbers against the official FDA enforcement report.

Where does this information come from?
All content is reproduced from FDA Structured Product Labelling data via openFDA. It is provided for identification and reference only and is not medical advice.